New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 16, 2013
07:05 EDTBLRXBioLineRx announces 'promising' BL-8040 initial Phase 2 results
BioLineRx announced "promising" initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia. The early results show that BL-8040, as a stand-alone therapy and in combination with high-dose Cytarabine, is safe at all doses tested to date, and triggers substantial mobilization of cancer cells from the bone marrow to the peripheral blood, thereby increasing the vulnerability of the cells to chemotherapy treatment. In addition, signs of robust apoptosis of cancer cells were observed following administration of the higher doses tested to date. The study has not yet reached the highest planned doses, suggesting that a strengthening of BL-8040's effects may be observed in future dosing cohorts. The primary endpoints of the study are to assess the safety and tolerability of BL-8040. Secondary endpoints include the pharmacokinetic profile of the drug and an efficacy evaluation, indicated by the extent of mobilization of cancer cells from the bone marrow to the peripheral blood, the level of cancer cell death and clinical responses.
News For BLRX From The Last 14 Days
Check below for free stories on BLRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2014
07:09 EDTBLRXBioLineRx announces investigator-initiated study for BL-8040
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use